Etrasimod: A New Oral Treatment Option for Ulcerative Colitis
The S1PR modulators are currently positioned to serve as a great treatment option for patients with moderate disease who are hesitant to escalate to a biologic treatment.
Read More
Risankizumab: A New Treatment Option for Crohn’s Disease
Risankizumab represents the first ever IL-23 treatment for adult patients with Crohn's disease approved by the FDA.
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Endocrinology Month in Review: December 2024
FDA News Month in Review: December 2024
Study Identifies Social Determinants of Suicide Mortality, Suicide Attempts